OTCMKTS:BGMD - BG Medicine Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.0210 -0.01 (-32.26 %) (As of 09/21/2018 03:56 PM ET)Previous Close$0.0330Today's Range$0.0210 - $0.025852-Week Range$0.02 - $0.09Volume26,551 shsAverage Volume8,782 shsMarket Capitalization$240,000.00P/E RatioN/ADividend YieldN/ABeta2.99 Company ProfileDiscussionChartEarnings HistoryFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BG Medicine, Inc. engages in development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts. Receive BGMD News and Ratings via Email Sign-up to receive the latest news and ratings for BGMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Diagnostic substances Sub-IndustryLife Sciences Tools & Services SectorMedical SymbolOTCMKTS:BGMD CUSIP08861T10 Webwww.bg-medicine.com Phone781-890-1199 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.57 million Price / Sales0.15 Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding Shares11,370,000Market Cap$240,000.00 BG Medicine (OTCMKTS:BGMD) Frequently Asked Questions What is BG Medicine's stock symbol? BG Medicine trades on the OTCMKTS under the ticker symbol "BGMD." How were BG Medicine's earnings last quarter? BG Medicine, Inc. (OTCMKTS:BGMD) announced its quarterly earnings data on Tuesday, November, 17th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter. The medical research company earned $334 million during the quarter, compared to analyst estimates of $695 million. View BG Medicine's Earnings History. Who are some of BG Medicine's key competitors? Some companies that are related to BG Medicine include IDEXX Laboratories (IDXX), IPSEN S A/S (IPSEY), Neogen (NEOG), Immunomedics (IMMU), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX) and Riot Blockchain (RIOT). Who are BG Medicine's key executives? BG Medicine's management team includes the folowing people: Dr. Paul R. Sohmer, CEO, Pres & Director (Age 69)Mr. Stephen P. Hall, CFO, Exec. VP & Treasurer (Age 67)Dr. Aram Adourian, Chief Scientific Officer (Age 48) Has BG Medicine been receiving favorable news coverage? Media coverage about BGMD stock has been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. BG Medicine earned a coverage optimism score of 0.18 on Accern's scale. They also assigned news coverage about the medical research company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for BG Medicine. How do I buy shares of BG Medicine? Shares of BGMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BG Medicine's stock price today? One share of BGMD stock can currently be purchased for approximately $0.0210. How big of a company is BG Medicine? BG Medicine has a market capitalization of $240,000.00 and generates $1.57 million in revenue each year. How can I contact BG Medicine? BG Medicine's mailing address is 303 Wyman Street Suite 300, Waltham MA, 02451. The medical research company can be reached via phone at 781-890-1199 or via email at [email protected] MarketBeat Community Rating for BG Medicine (OTCMKTS BGMD)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 72 (Vote Outperform)Underperform Votes: 66 (Vote Underperform)Total Votes: 138MarketBeat's community ratings are surveys of what our community members think about BG Medicine and other stocks. Vote "Outperform" if you believe BGMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BGMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/21/2018 by MarketBeat.com StaffFeatured Article: What do investors mean by earnings per share?